Following multibillion dollar asset acquisitions and artificial intelligence (AI)-centred deals, Servier’s head of business development outlines how one of France’s leading pharma companies is planning for the future amidst a changing geopolitical scene.
In 2026, Servier completed the $2.5 billion acquisition of the oncology developer Day One Biopharmaceuticals and acquired the muscular dystrophy business of Edgewise Therapeutics for around $2.65 billion, following major AI-focused deals with InSilico Medicine and Iktos. In this latest episode, Pharmaceutical Technology reporter Frankie Fattorini speaks with the head of business development Frederic Scaerou to understand how these deals are shaping Servier as the French multinational navigates shifting global industry trends.
